Inhibikase Therapeutics Inc Share Price Today: Live Updates & Key Insights

Inhibikase Therapeutics Inc share price today is $1.785, up -1.64%. The stock opened at $1.84 against the previous close of $1.83, with an intraday high of $1.87 and low of $1.775.

Inhibikase Therapeutics Inc Share Price Chart

Inhibikase Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Inhibikase Therapeutics Inc Share Price Performance

$1.785 -0.0164(-1.64%) IKT at 23 Mar 2026 01:38 PM Biotechnology
Lowest Today 1.775
Highest Today 1.87
Today’s Open 1.84
Prev. Close 1.83
52 Week High 2.46
52 Week Low 1.33
Day’s Range: Low 1.775 High 1.87
52-Week Range: Low 1.33 High 2.46
1 day return -
1 Week return -9.57
1 month return -0.27
3 month return +7.48
6 month return +6.21
1 year return -24.26
3 year return -53.7
5 year return -94.71
10 year return -

Inhibikase Therapeutics Inc Institutional Holdings

Sands Capital Ventures, LLC 10.74

Fairmount Funds Management LLC 7.11

ADAR1 Capital Management LLC 6.65

Soleus Capital Management, L.P. 5.22

Trails Edge Capital Partners, LP 5.09

Siren, L.L.C. 4.82

Perceptive Advisors LLC 4.47

COMMODORE CAPITAL LP 4.45

Vanguard Group Inc 3.76

Squadron Capital Management LLC 3.48

Nantahala Capital Management, LLC 3.24

Saturn V Capital Management LLC 3.18

Spruce Street Capital LP 2.95

Vanguard Total Stock Mkt Idx Inv 2.83

BlackRock Inc 2.54

Blackstone Inc 2.18

Stonepine Capital Management Llc 1.94

Kalehua Capital Management LLC 1.44

iShares Russell 2000 ETF 1.05

Citadel Advisors Llc 1.03

Geode Capital Management, LLC 0.93

Exome Asset Management LLC 0.49

Fidelity Small Cap Index 0.49

iShares Russell 2000 Value ETF 0.38

Vanguard Institutional Extnd Mkt Idx Tr 0.31

Vanguard Russell 2000 ETF 0.24

State St Russell Sm Cap® Indx SL Cl I 0.17

Fidelity Extended Market Index 0.16

iShares Micro-Cap ETF 0.13

Schwab Small Cap Index 0.13

NT R2000 Index Fund - NL 0.11

NT R2000 Index Fund - DC - NL - 3 0.09

iShares Russell 2000 Small-Cap Idx Instl 0.09

Vanguard Instl Ttl Stck Mkt Idx Tr 0.07

Russell 2500™ Index Fund F 0.07

Nuveen Small Cap Blend Idx R6 0.06

Spartan Small Cap Index Pool K 0.06

Fidelity Small Cap Value Index 0.05

State St Russell Sm/Mid Cp® Indx SL Cl I 0.05

Vanguard Balanced Index Inv 0.05

Inhibikase Therapeutics Inc Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Inhibikase Therapeutics Inc Fundamentals

Market Cap 119.23 M

PB Ratio 3.0442

PE Ratio 0.0

Enterprise Value 134.29 M

Total Assets 98.60 M

Volume 8868806

Inhibikase Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:123440 0.1M, FY21:3100605 3.1M, FY20:698468 0.7M, FY19:1122740 1.1M

Annual Profit FY23:null 0.0M, FY22:123440 0.1M, FY21:3100605 3.1M, FY20:698468 0.7M, FY19:null 0.0M

Annual Net worth FY23:-19129995 -19.1M, FY22:-17905249 -17.9M, FY21:-14805986 -14.8M, FY20:-2877296 -2.9M, FY19:-5747818 -5.7M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-23688 -0.0M, Q2/2025:-24157 -0.0M, Q1/2025:-12654 -0.0M, Q3/2024:null 0.0M, Q2/2024:-6569 -0.0M

Quarterly Net worth Q3/2025:-11930280 -11.9M, Q2/2025:-9915523 -9.9M, Q1/2025:-13678735 -13.7M, Q3/2024:-5778066 -5.8M, Q2/2024:-4959608 -5.0M

About Inhibikase Therapeutics Inc & investment objective

Company Information Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.

Organisation Biotechnology

Employees 15

Industry Biotechnology

CEO Mr. Mark T. Iwicki

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Inhibikase Therapeutics Inc FAQs

What is the share price of Inhibikase Therapeutics Inc today?

The current share price of Inhibikase Therapeutics Inc is $1.785.

Can I buy Inhibikase Therapeutics Inc shares in India?

Yes, Indian investors can buy Inhibikase Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Inhibikase Therapeutics Inc shares in India?

You can easily invest in Inhibikase Therapeutics Inc shares from India by:

Can I buy fractional shares of Inhibikase Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Inhibikase Therapeutics Inc?

Inhibikase Therapeutics Inc has a market cap of $119.23 M.

In which sector does Inhibikase Therapeutics Inc belong?

Inhibikase Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Inhibikase Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Inhibikase Therapeutics Inc?

The PE ratio of Inhibikase Therapeutics Inc is N/A and the PB ratio is 3.04.